Evidence map›Paper›PMID 24519175›Full record

ArticleIn vitro cellular & developmental biology. Animal2014

Effect of Gsk3 inhibitor CHIR99021 on aneuploidy levels in rat embryonic stem cells.

Anagha S Bock, Nathan D Leigh, Elizabeth C Bryda

Open access · hybridAbstract read
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anagha S BockRat Resource and Research Center, Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, 4011 Discovery Drive, Columbia, MO, 65201, USA.
Nathan D Leigh
Elizabeth C Bryda
University of Missouri · US

Funding

ResourceP40OD011062 · OD · UNIVERSITY OF MISSOURI-COLUMBIA · PI Elizabeth C Bryda · 2012 to 2026
$24.0M
NIH HHS P40 OD011062
6 · The paper itself

Abstract

Germline competent embryonic stem (ES) cells can serve as a tool to create genetically engineered rat strains used to elucidate gene function or provide disease models. In optimum culture conditions, ES cells are able to retain their pluripotent state. The type of components present and their concentration in ES cell culture media greatly influences characteristics of ES cells including the ability to maintain the cells in a pluripotent state. We routinely use 2i media containing inhibitors CHIR99021 and PD0325901 to culture rat ES cells. CHIR99021 specifically inhibits the Gsk3β pathway. We have found that the vendor source of CHIR99021 has a measurable influence on the level of aneuploidy seen over time as rat ES cells are passaged. Karyotyping of three different rat ES cell lines passaged multiple times showed increased aneuploidy when CHIR99021 from source B was used. Mass spectrometry analysis of this inhibitor showed the presence of unexpected synthetic small molecules, which might directly or indirectly cause increases in chromosome instability. Identifying these molecules could further understanding of their influence on chromosome stability and indicate how to improve synthesis of this media component to prevent deleterious effects in culture.

Indexed as

AneuploidyAnimalsBenzamidesCell LineDiphenylamineEmbryonic Stem CellsGlycogen Synthase Kinase 3KaryotypePyridinesPyrimidinesRatsBenzamidesChir 99021DiphenylamineGlycogen Synthase Kinase 3mirdametinibPyridinesPyrimidines

Identifiers

PMID24519175
PMCPMC4062835
OpenAlexW2056188654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.